Evaluation of the program to eliminate lymphatic filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach.
Identifieur interne : 001F92 ( Ncbi/Merge ); précédent : 001F91; suivant : 001F93Evaluation of the program to eliminate lymphatic filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach.
Auteurs : Margaret Fraser [Vanuatu] ; George Taleo ; Fasihah Taleo ; James Yaviong ; Morris Amos ; Mark Babu ; Morris KalkoaSource :
- The American journal of tropical medicine and hygiene [ 0002-9637 ] ; 2005.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Albendazole (administration et posologie), Albendazole (usage thérapeutique), Animaux, Antigènes d'helminthe (sang), Association de médicaments, Connaissances, attitudes et pratiques en santé, Diéthylcarbamazine (administration et posologie), Diéthylcarbamazine (usage thérapeutique), Enfant, Enfant d'âge préscolaire, Femelle, Filaricides (administration et posologie), Filaricides (usage thérapeutique), Filariose lymphatique (), Filariose lymphatique (traitement médicamenteux), Filariose lymphatique (épidémiologie), Humains, Literie et linges, Mâle, Prévalence, Sujet âgé, Surveillance sentinelle, Vanuatu (épidémiologie), Wuchereria bancrofti (isolement et purification), Évaluation de programme.
- MESH :
- administration et posologie : Albendazole, Diéthylcarbamazine, Filaricides.
- isolement et purification : Wuchereria bancrofti.
- sang : Antigènes d'helminthe.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Albendazole, Diéthylcarbamazine, Filaricides.
- épidémiologie : Filariose lymphatique, Vanuatu.
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Association de médicaments, Connaissances, attitudes et pratiques en santé, Enfant, Enfant d'âge préscolaire, Femelle, Filariose lymphatique, Humains, Literie et linges, Mâle, Prévalence, Sujet âgé, Surveillance sentinelle, Évaluation de programme.
- Wicri :
- geographic : Vanuatu.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Albendazole (administration & dosage), Albendazole (therapeutic use), Animals, Antigens, Helminth (blood), Bedding and Linens, Child, Child, Preschool, Diethylcarbamazine (administration & dosage), Diethylcarbamazine (therapeutic use), Drug Therapy, Combination, Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (epidemiology), Elephantiasis, Filarial (prevention & control), Female, Filaricides (administration & dosage), Filaricides (therapeutic use), Health Knowledge, Attitudes, Practice, Humans, Male, Middle Aged, Prevalence, Program Evaluation, Sentinel Surveillance, Vanuatu (epidemiology), Wuchereria bancrofti (isolation & purification).
- MESH :
- chemical , administration & dosage : Albendazole, Diethylcarbamazine, Filaricides.
- chemical , blood : Antigens, Helminth.
- chemical , therapeutic use : Albendazole, Diethylcarbamazine, Filaricides.
- geographic , epidemiology : Vanuatu.
- drug therapy : Elephantiasis, Filarial.
- epidemiology : Elephantiasis, Filarial.
- isolation & purification : Wuchereria bancrofti.
- prevention & control : Elephantiasis, Filarial.
- Adolescent, Adult, Aged, Animals, Bedding and Linens, Child, Child, Preschool, Drug Therapy, Combination, Female, Health Knowledge, Attitudes, Practice, Humans, Male, Middle Aged, Prevalence, Program Evaluation, Sentinel Surveillance.
Abstract
This report presents the results of the Vanuatu mid-term evaluation of the lymphatic filariasis elimination program being implemented countrywide. Vanuatu is one of the first countries to initiate this program as part of the Global Program for Elimination of Lymphatic Filariasis, based on a five-year annual mass drug administration (MDA) of albendazole and diethylcarbamazine and complemented in Vanuatu by extensive coverage with bed nets. This paper reports results of 561 persons tested at eight sentinel sites following two years of MDA. Coverage was 72% and bed net use was more than 70%. Antigen prevalence was reduced by 63% (from 22% to 8%) and prevalence of microfilaremia prevalence was reduced by 93% (from 12% to 0.8%). Results of surveys of health workers and the community are also reported, and the methodology used for this evaluation is discussed.
PubMed: 16222021
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003B79
- to stream PubMed, to step Curation: 003B79
- to stream PubMed, to step Checkpoint: 003B79
Links to Exploration step
pubmed:16222021Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of the program to eliminate lymphatic filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach.</title>
<author><name sortKey="Fraser, Margaret" sort="Fraser, Margaret" uniqKey="Fraser M" first="Margaret" last="Fraser">Margaret Fraser</name>
<affiliation wicri:level="1"><nlm:affiliation>Vector Borne Disease Unit, Vanuatu Ministry Of Health, Port Vila, Vanuatu. margaret.fraser@liverpool.ac.uk</nlm:affiliation>
<country xml:lang="fr">Vanuatu</country>
<wicri:regionArea>Vector Borne Disease Unit, Vanuatu Ministry Of Health, Port Vila</wicri:regionArea>
<wicri:noRegion>Port Vila</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Taleo, George" sort="Taleo, George" uniqKey="Taleo G" first="George" last="Taleo">George Taleo</name>
</author>
<author><name sortKey="Taleo, Fasihah" sort="Taleo, Fasihah" uniqKey="Taleo F" first="Fasihah" last="Taleo">Fasihah Taleo</name>
</author>
<author><name sortKey="Yaviong, James" sort="Yaviong, James" uniqKey="Yaviong J" first="James" last="Yaviong">James Yaviong</name>
</author>
<author><name sortKey="Amos, Morris" sort="Amos, Morris" uniqKey="Amos M" first="Morris" last="Amos">Morris Amos</name>
</author>
<author><name sortKey="Babu, Mark" sort="Babu, Mark" uniqKey="Babu M" first="Mark" last="Babu">Mark Babu</name>
</author>
<author><name sortKey="Kalkoa, Morris" sort="Kalkoa, Morris" uniqKey="Kalkoa M" first="Morris" last="Kalkoa">Morris Kalkoa</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:16222021</idno>
<idno type="pmid">16222021</idno>
<idno type="wicri:Area/PubMed/Corpus">003B79</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003B79</idno>
<idno type="wicri:Area/PubMed/Curation">003B79</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003B79</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003B79</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003B79</idno>
<idno type="wicri:Area/Ncbi/Merge">001F92</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation of the program to eliminate lymphatic filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach.</title>
<author><name sortKey="Fraser, Margaret" sort="Fraser, Margaret" uniqKey="Fraser M" first="Margaret" last="Fraser">Margaret Fraser</name>
<affiliation wicri:level="1"><nlm:affiliation>Vector Borne Disease Unit, Vanuatu Ministry Of Health, Port Vila, Vanuatu. margaret.fraser@liverpool.ac.uk</nlm:affiliation>
<country xml:lang="fr">Vanuatu</country>
<wicri:regionArea>Vector Borne Disease Unit, Vanuatu Ministry Of Health, Port Vila</wicri:regionArea>
<wicri:noRegion>Port Vila</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Taleo, George" sort="Taleo, George" uniqKey="Taleo G" first="George" last="Taleo">George Taleo</name>
</author>
<author><name sortKey="Taleo, Fasihah" sort="Taleo, Fasihah" uniqKey="Taleo F" first="Fasihah" last="Taleo">Fasihah Taleo</name>
</author>
<author><name sortKey="Yaviong, James" sort="Yaviong, James" uniqKey="Yaviong J" first="James" last="Yaviong">James Yaviong</name>
</author>
<author><name sortKey="Amos, Morris" sort="Amos, Morris" uniqKey="Amos M" first="Morris" last="Amos">Morris Amos</name>
</author>
<author><name sortKey="Babu, Mark" sort="Babu, Mark" uniqKey="Babu M" first="Mark" last="Babu">Mark Babu</name>
</author>
<author><name sortKey="Kalkoa, Morris" sort="Kalkoa, Morris" uniqKey="Kalkoa M" first="Morris" last="Kalkoa">Morris Kalkoa</name>
</author>
</analytic>
<series><title level="j">The American journal of tropical medicine and hygiene</title>
<idno type="ISSN">0002-9637</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Albendazole (administration & dosage)</term>
<term>Albendazole (therapeutic use)</term>
<term>Animals</term>
<term>Antigens, Helminth (blood)</term>
<term>Bedding and Linens</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Diethylcarbamazine (administration & dosage)</term>
<term>Diethylcarbamazine (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Elephantiasis, Filarial (drug therapy)</term>
<term>Elephantiasis, Filarial (epidemiology)</term>
<term>Elephantiasis, Filarial (prevention & control)</term>
<term>Female</term>
<term>Filaricides (administration & dosage)</term>
<term>Filaricides (therapeutic use)</term>
<term>Health Knowledge, Attitudes, Practice</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prevalence</term>
<term>Program Evaluation</term>
<term>Sentinel Surveillance</term>
<term>Vanuatu (epidemiology)</term>
<term>Wuchereria bancrofti (isolation & purification)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Albendazole (administration et posologie)</term>
<term>Albendazole (usage thérapeutique)</term>
<term>Animaux</term>
<term>Antigènes d'helminthe (sang)</term>
<term>Association de médicaments</term>
<term>Connaissances, attitudes et pratiques en santé</term>
<term>Diéthylcarbamazine (administration et posologie)</term>
<term>Diéthylcarbamazine (usage thérapeutique)</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Filaricides (administration et posologie)</term>
<term>Filaricides (usage thérapeutique)</term>
<term>Filariose lymphatique ()</term>
<term>Filariose lymphatique (traitement médicamenteux)</term>
<term>Filariose lymphatique (épidémiologie)</term>
<term>Humains</term>
<term>Literie et linges</term>
<term>Mâle</term>
<term>Prévalence</term>
<term>Sujet âgé</term>
<term>Surveillance sentinelle</term>
<term>Vanuatu (épidémiologie)</term>
<term>Wuchereria bancrofti (isolement et purification)</term>
<term>Évaluation de programme</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albendazole</term>
<term>Diethylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antigens, Helminth</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term>
<term>Diethylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Vanuatu</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albendazole</term>
<term>Diéthylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Wuchereria bancrofti</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Wuchereria bancrofti</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Antigènes d'helminthe</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term>
<term>Diéthylcarbamazine</term>
<term>Filaricides</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term>
<term>Vanuatu</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Animals</term>
<term>Bedding and Linens</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Health Knowledge, Attitudes, Practice</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prevalence</term>
<term>Program Evaluation</term>
<term>Sentinel Surveillance</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Association de médicaments</term>
<term>Connaissances, attitudes et pratiques en santé</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Filariose lymphatique</term>
<term>Humains</term>
<term>Literie et linges</term>
<term>Mâle</term>
<term>Prévalence</term>
<term>Sujet âgé</term>
<term>Surveillance sentinelle</term>
<term>Évaluation de programme</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Vanuatu</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This report presents the results of the Vanuatu mid-term evaluation of the lymphatic filariasis elimination program being implemented countrywide. Vanuatu is one of the first countries to initiate this program as part of the Global Program for Elimination of Lymphatic Filariasis, based on a five-year annual mass drug administration (MDA) of albendazole and diethylcarbamazine and complemented in Vanuatu by extensive coverage with bed nets. This paper reports results of 561 persons tested at eight sentinel sites following two years of MDA. Coverage was 72% and bed net use was more than 70%. Antigen prevalence was reduced by 63% (from 22% to 8%) and prevalence of microfilaremia prevalence was reduced by 93% (from 12% to 0.8%). Results of surveys of health workers and the community are also reported, and the methodology used for this evaluation is discussed.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16222021</PMID>
<DateCreated><Year>2005</Year>
<Month>10</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted><Year>2006</Year>
<Month>01</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9637</ISSN>
<JournalIssue CitedMedium="Print"><Volume>73</Volume>
<Issue>4</Issue>
<PubDate><Year>2005</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>The American journal of tropical medicine and hygiene</Title>
<ISOAbbreviation>Am. J. Trop. Med. Hyg.</ISOAbbreviation>
</Journal>
<ArticleTitle>Evaluation of the program to eliminate lymphatic filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach.</ArticleTitle>
<Pagination><MedlinePgn>753-8</MedlinePgn>
</Pagination>
<Abstract><AbstractText>This report presents the results of the Vanuatu mid-term evaluation of the lymphatic filariasis elimination program being implemented countrywide. Vanuatu is one of the first countries to initiate this program as part of the Global Program for Elimination of Lymphatic Filariasis, based on a five-year annual mass drug administration (MDA) of albendazole and diethylcarbamazine and complemented in Vanuatu by extensive coverage with bed nets. This paper reports results of 561 persons tested at eight sentinel sites following two years of MDA. Coverage was 72% and bed net use was more than 70%. Antigen prevalence was reduced by 63% (from 22% to 8%) and prevalence of microfilaremia prevalence was reduced by 93% (from 12% to 0.8%). Results of surveys of health workers and the community are also reported, and the methodology used for this evaluation is discussed.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fraser</LastName>
<ForeName>Margaret</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Vector Borne Disease Unit, Vanuatu Ministry Of Health, Port Vila, Vanuatu. margaret.fraser@liverpool.ac.uk</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Taleo</LastName>
<ForeName>George</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Taleo</LastName>
<ForeName>Fasihah</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yaviong</LastName>
<ForeName>James</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Amos</LastName>
<ForeName>Morris</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Babu</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kalkoa</LastName>
<ForeName>Morris</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Am J Trop Med Hyg</MedlineTA>
<NlmUniqueID>0370507</NlmUniqueID>
<ISSNLinking>0002-9637</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000947">Antigens, Helminth</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005369">Filaricides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>F4216019LN</RegistryNumber>
<NameOfSubstance UI="D015766">Albendazole</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber>
<NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000947" MajorTopicYN="N">Antigens, Helminth</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001512" MajorTopicYN="N">Bedding and Linens</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007722" MajorTopicYN="N">Health Knowledge, Attitudes, Practice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015397" MajorTopicYN="Y">Program Evaluation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018571" MajorTopicYN="N">Sentinel Surveillance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009514" MajorTopicYN="N" Type="Geographic">Vanuatu</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014958" MajorTopicYN="N">Wuchereria bancrofti</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>10</Month>
<Day>14</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>1</Month>
<Day>6</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>10</Month>
<Day>14</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16222021</ArticleId>
<ArticleId IdType="pii">73/4/753</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Vanuatu</li>
</country>
</list>
<tree><noCountry><name sortKey="Amos, Morris" sort="Amos, Morris" uniqKey="Amos M" first="Morris" last="Amos">Morris Amos</name>
<name sortKey="Babu, Mark" sort="Babu, Mark" uniqKey="Babu M" first="Mark" last="Babu">Mark Babu</name>
<name sortKey="Kalkoa, Morris" sort="Kalkoa, Morris" uniqKey="Kalkoa M" first="Morris" last="Kalkoa">Morris Kalkoa</name>
<name sortKey="Taleo, Fasihah" sort="Taleo, Fasihah" uniqKey="Taleo F" first="Fasihah" last="Taleo">Fasihah Taleo</name>
<name sortKey="Taleo, George" sort="Taleo, George" uniqKey="Taleo G" first="George" last="Taleo">George Taleo</name>
<name sortKey="Yaviong, James" sort="Yaviong, James" uniqKey="Yaviong J" first="James" last="Yaviong">James Yaviong</name>
</noCountry>
<country name="Vanuatu"><noRegion><name sortKey="Fraser, Margaret" sort="Fraser, Margaret" uniqKey="Fraser M" first="Margaret" last="Fraser">Margaret Fraser</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F92 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001F92 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:16222021 |texte= Evaluation of the program to eliminate lymphatic filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:16222021" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |